Havanka-Kanniainen H, Hokkanen E, Myllylä V V
Cephalalgia. 1987 Mar;7(1):7-13. doi: 10.1046/j.1468-2982.1987.0701007.x.
The efficacy of nimodipine in comparison with that of pizotifen was assessed in the prophylaxis of migraine in a double-blind cross-over study, in which a double-dummy technique was also utilized. The study was carried out on 43 migraine patients, of whom 15 had classic and 28 had common migraine. A 4-week run-in placebo period preceded the drug treatments, the drug treatments lasted 12 weeks, and there was a washout placebo period of 4 weeks between nimodipine and pizotifen treatments. The dosages used were 40 mg three times daily for nimodipine and 0.5 mg three times daily for pizotifen. Both nimodipine and pizotifen proved to be better than placebo, the number of migraine attacks showing a significant reduction. There was no difference between nimodipine and pizotifen in antimigrainous efficacy, but there were fewer side effects during the nimodipine period. The results suggest that nimodipine is an effective drug for the prophylaxis of migraine, with few side effects and therapeutic efficacy equal to that of pizotifen.
在一项双盲交叉研究中，采用双模拟技术，对尼莫地平与苯噻啶预防偏头痛的疗效进行了评估。该研究对43例偏头痛患者进行，其中15例为典型偏头痛，28例为普通偏头痛。在药物治疗前有一个为期4周的安慰剂导入期，药物治疗持续12周，在尼莫地平和苯噻啶治疗之间有一个为期4周的洗脱安慰剂期。使用的剂量为尼莫地平每日3次，每次40mg，苯噻啶每日3次，每次0.5mg。尼莫地平和苯噻啶均被证明优于安慰剂，偏头痛发作次数显著减少。尼莫地平和苯噻啶在抗偏头痛疗效上无差异，但在尼莫地平治疗期间副作用较少。结果表明，尼莫地平是一种预防偏头痛的有效药物，副作用少，治疗效果与苯噻啶相当。
